Teva Pharmaceutical Industries has patented an inhaler for powder medication delivery. The device features a unique design with specific cross-sectional areas for efficient airflow. It includes a deagglomerator with a swirl chamber for optimal powder dispersion. GlobalData’s report on Teva Pharmaceutical Industries gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Teva Pharmaceutical Industries, Cancer treatment biomarkers was a key innovation area identified from patents. Teva Pharmaceutical Industries's grant share as of April 2024 was 38%. Grant share is based on the ratio of number of grants to total number of patents.
Inhaler with multiple outlets and deagglomerator for powder medication
A newly granted patent (Publication Number: US11969544B2) discloses an innovative inhaler designed for the inhalation of powder medication. The inhaler features an inhaler body with at least one reservoir containing powder medication, an air inlet, and an outlet for the transmission of air and medication to the patient. The outlet includes a primary outlet for the medication and secondary outlets for air alone, along with a deagglomerator with a swirl chamber to ensure effective delivery of the medication. The design of the inhaler aims to optimize the flow of air and powder medication, enhancing the overall effectiveness of the inhalation process.
Furthermore, the patent claims detail specific configurations and features of the inhaler, such as the cross-sectional areas of the outlets, the shape of the air inlet, and the delivery passageway to the deagglomerator. The method of treating respiratory diseases or disorders using the inhaler is also outlined, emphasizing the administration of therapeutically effective amounts of active ingredients. The respiratory conditions targeted include asthma and chronic obstructive pulmonary disease, with specific active ingredients mentioned for treatment. Overall, the patented inhaler offers a novel approach to delivering powder medication for respiratory conditions, with a focus on optimizing particle delivery and enhancing patient outcomes.
To know more about GlobalData’s detailed insights on Teva Pharmaceutical Industries, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
